Study of Pembrolizumab, Carboplatin, Paclitaxel, and Radiation for the Treatment of Early-Stage Anal Cancer (NCT06493019)
A Phase II Study of Pembrolizumab, Carboplatin, Paclitaxel, and Radiation for the Treatment of Early-Stage Anal Cancer
🩺 Plain-English Summary (8th-Grade Level)
A single arm phase II study of pembrolizumab, carboplatin, paclitaxel, and radiation for the treatment of early-stage anal cancer. There are 2 treatments phases and then surveillance. The first treatment phase is the chemoradiation phase (Cycle 1-6, weekly cycles) which is followed by the maintenance phase (Cycle 7-14, 6 week cycles).
Who can join: Review the eligibility criteria below.
Location: Indiana University Melvin and Bren Simon Comprehensive Cancer Center — Indianapolis, Indiana
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (4 Sites)
- Indiana University Melvin and Bren Simon Comprehensive Cancer Center — Indianapolis, Indiana
- University of Maryland — Baltimore, Maryland
- Rutgers Cancer Institute of New Jersey — New Brunswick, New Jersey
- University of Wisconsin — Madison, Wisconsin
📞 Contact the Study Coordinator
Phone: (608) 262-0439
Email: ddeming@medicine.wisc.edu
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Anal Cancer
- ASSESSING THE GAY MALE EXPERIENCE WITH ANAL CANCER PREVENTION STRATEGIES — Minneapolis, Minnesota
- REDEL Trial: Reduced Elective Nodal Dose for Anal Cancer Toxicity Mitigation — Cincinnati, Ohio
- Self-sampling to Optimize Anal Lesion Outcomes — Chicago, Illinois
- ctHPVDNA Response-Adapted Chemoradiation +/- Retifanlimab Treatment in Locally-Advanced Anal Cancer — Cleveland, Ohio
Explore by condition: All Anal Cancer clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.